Peregrine Capital Management LLC Acquires Shares of 62,242 LivaNova PLC $LIVN

Peregrine Capital Management LLC acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN) in the 4th quarter, Holdings Channel.com reports. The fund acquired 62,242 shares of the company’s stock, valued at approximately $3,830,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of Wyoming bought a new position in shares of LivaNova during the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC boosted its holdings in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. Quarry LP bought a new position in shares of LivaNova during the 3rd quarter valued at about $36,000. UMB Bank n.a. boosted its holdings in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after purchasing an additional 306 shares during the last quarter. Finally, Bayforest Capital Ltd boosted its holdings in shares of LivaNova by 44.8% during the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after purchasing an additional 284 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

LivaNova stock opened at $64.20 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16. LivaNova PLC has a 1-year low of $35.00 and a 1-year high of $71.92. The firm has a market capitalization of $3.51 billion, a P/E ratio of -14.39 and a beta of 0.97. The company’s 50-day moving average is $64.71 and its 200 day moving average is $61.53.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. During the same period in the prior year, the company posted $0.81 EPS. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Research analysts forecast that LivaNova PLC will post 3.66 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on LIVN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. Barclays upped their target price on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research report on Wednesday, February 25th. Piper Sandler restated an “overweight” rating and set a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Finally, Needham & Company LLC upped their target price on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $74.78.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.